Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR-A1811 in previously treated HER2-expressing/amplified biliary tract cancer
CTR20241673Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in biliary cancer, sponsored by Hengrui Therapeutics. Started Jul 2024; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20241673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241673.